[1] [1] TORRE L A, BRAY F, SIEGEL R L,et al. Global cancer statistics,2012[J]. CA A Cancer J Clinicians, 2015, 65(2): 87-108. DOI:10.3322/caac.21262.

[3] [3] XU J F, FANG Y F, CHEN K L,et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer[J]. Clin Cancer Res, 2022, 28(16): 3590-3602. DOI:10.1158/1078-0432.CCR-22-0296.

[4] [4] YANG Z C, ZI Q, XU K,et al. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm[J/OL]. Int Immunopharmacol, 2021, 90: 107238[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/33316739/. DOI:10.1016/j.intimp.2020.107238.

[5] [5] CHEN D S, MELLMAN I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330. DOI:10.1038/nature21349.

[6] [6] XU J S, LIAO K L, YANG X,et al. Using single-cell sequencing technology to detect circulating tumor cells in solid tumors[J/OL]. Mol Cancer, 2021, 20(1): 104[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/34412644/. DOI:10.1186/s12943-021-01392-w.

[7] [7] KARANTZA V. Keratins in health and cancer: more than mere epithelial cell markers[J]. Oncogene, 2011, 30(2): 127-138. DOI:10.1038/onc.2010.456.

[8] [8] TANIMURA N, FUJITA Y. Epithelial defense against cancer(EDAC)[J]. Semin Cancer Biol, 2020, 63: 44-48. DOI:10.1016/j.semcancer.2019.05.011.

[9] [9] RNBURG M, DESBOIS M, LU S,et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer[J]. Cancer Cell, 2021, 39(7): 928-944. e6. DOI:10.1016/j.ccell.2021.04.004.

[10] [10] GAO Y, SHI H, ZHAO H Y,et al. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer[J/OL]. Clin Transl Med, 2023, 13(9): e1416[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/37712139/. DOI:10.1002/ctm2.1416.

[12] [12] SIEGEL R L, MILLER K D, FUCHS H E,et al. Cancer statistics,2022[J]. CA A Cancer J Clinicians, 2022, 72(1): 7-33. DOI:10.3322/caac.21708.

[14] [14] COUCH F J, NATHANSON K L, OFFIT K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention[J]. Science, 2014, 343(6178): 1466-1470. DOI:10.1126/science.1251827.

[15] [15] KRUSE B, BUZZAI A C, SHRIDHAR N,et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours[J]. Nature, 2023, 618(7967): 1033-1040. DOI:10.1038/s41586-023-06199-x.

[16] [16] ZHANG X, JI L L, LI M O. Control of tumor-associated macrophage responses by nutrient acquisition and metabolism[J]. Immunity, 2023, 56(1): 14-31. DOI:10.1016/j.immuni.2022.12.003.

[17] [17] HE M Y, ROUSSAK K, MA F Y,et al. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses[J/OL]. Science, 2023, 379(6633): eabg2752[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/36795805/. DOI:10.1126/science.abg2752.

[18] [18] DOCHEZ V, CAILLON H, VAUCEL E,et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review[J/OL]. J Ovarian Res, 2019, 12(1): 28[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/30917847/. DOI:10.1186/s13048-019-0503-7.

[19] [19] HELLSTRM I, RAYCRAFT J, HAYDEN-LEDBETTER M,et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J]. Cancer Res, 2003, 63(13): 3695-3700.

[20] [20] BRACHOVA P, MUETING S R, CARLSON M J,et al. TP53 oncomorphic mutations predict resistance to platinum-and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma[J]. Int J Oncol, 2015, 46(2): 607-618. DOI:10.3892/ijo.2014.2747.

[21] [21] ZHU L L, ZHOU X F, GU M D,et al. Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer[J]. Nat Cell Biol, 2022, 24(7): 1165-1176. DOI:10.1038/s41556-022-00942-8.

[22] [22] SUTTERWALA F S, NOEL G J, CLYNES R,et al. Selective suppression of interleukin-12 induction after macrophage receptor ligation[J]. J Exp Med, 1997, 185(11): 1977-1985. DOI:10.1084/jem.185.11.1977.

[23] [23] SUTTERWALA F S, NOEL G J, SALGAME P,et al. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type Ⅰ[J]. J Exp Med, 1998, 188(1): 217-222. DOI:10.1084/jem.188.1.217.

[24] [24] MARTINEZ F O, SICA A, MANTOVANI A,et al. Macrophage activation and polarization[J]. Front Biosci, 2008, 13: 453-461. DOI:10.2741/2692.

[25] [25] NISHIKAWA H, KOYAMA S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies[J/OL]. J Immunother Cancer, 2021, 9(7): e002591[2024-10-06].. https://pubmed.ncbi.nlm.nih.gov/34330764/. DOI:10.1136/jitc-2021-002591.

[26] [26] LI C X, JIANG P, WEI S H,et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects[J/OL]. Mol Cancer, 2020, 19(1): 116[2024-10-06]. https://pubmed.ncbi.nlm.nih.gov/32680511/. DOI:10.1186/s12943-020-01234-1.